FDA panel to assess safety of popular injectable peptides
The FDA's Pharmacy Compounding Advisory Committee will meet to evaluate whether compounding pharmacies can produce seven widely used wellness peptides, amid concerns over limited clinical data.
The Food and Drug Administration has convened the Pharmacy Compounding Advisory Committee for a two-day meeting to consider allowing compounding pharmacies to manufacture seven injectable peptides that have become popular in the wellness market. The panel, which will meet from Thursday morning through Friday afternoon, will review evidence on compounds such as TB-500, BPC-157 and MOTS-C. None of these substances have completed the large-scale clinical trials required for full FDA drug approval.
Cell and molecular biologist Paul Knoepfler of the University of California, Davis, warned that the products are "very risky" because they have not been scientifically proven. The FDA’s own career scientists have expressed similar concerns, noting that most data come from pre-clinical animal studies and that human evidence is sparse or absent for several of the peptides.
Proponents argue that current restrictions have driven a grey market of overseas suppliers, creating safety risks for consumers who obtain unvetted products. Wellness influencer Gary Brecka, whose company markets peptides, said demand has simply moved underground and will not disappear.
The committee will examine data linking the peptides to conditions such as migraines, ulcerative colitis, opioid withdrawal and wound healing. If the FDA reclassifies the substances, clinicians could prescribe them beyond those narrow indications. Dr. Anant Vinjamoori, chief medical officer of Hims & Hers, acknowledged the limited clinical evidence but cited a decade of practitioner experience suggesting potential health benefits.
The meeting occurs amid broader political debate, with Health Secretary Robert F. Kennedy Jr. advocating for looser regulations on peptides. Recent changes to the advisory committee’s roster added members with industry ties, prompting questions about the panel’s composition. Knoepfler cautioned that permitting compounding without robust data could undermine the FDA’s authority and consistency.